Murchinson’s Sarepta Therapeutics SRPT Stock Holding History

Murchinson’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-25,000	Closed	-$1.94M	–	117
2021 Q2	$1.94M	Buy	+25,000	New	+$1.9M	0.7%	37

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Murchinson's SRPT Position: Q3 2021 in Review

Murchinson sold out of Sarepta Therapeutics (SRPT) in Q3 2021, closing a stake of 25,000 shares — an estimated $1.94M sold.

Murchinson first reported a position in SRPT in Q2 2021 and held it in 1 quarter. The position peaked at $1.94M in Q2 2021. 307 funds tracked by Wall St. Rank hold SRPT as of Q3 2021.

Murchinson reported no remaining Sarepta Therapeutics position as of Q3 2021 after selling out during the quarter.
Murchinson sold 25,000 Sarepta Therapeutics shares in Q3 2021, an estimated $1.94M.
Murchinson first reported a position in Sarepta Therapeutics in Q2 2021 and held it in 1 quarter.
Murchinson's Sarepta Therapeutics position peaked at $1.94M in Q2 2021.
307 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2021.

Based on Murchinson's 13F filing for Q3 2021, filed 15 Nov 2021.